[go: up one dir, main page]

HUE061898T2 - Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok - Google Patents

Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok

Info

Publication number
HUE061898T2
HUE061898T2 HUE18853233A HUE18853233A HUE061898T2 HU E061898 T2 HUE061898 T2 HU E061898T2 HU E18853233 A HUE18853233 A HU E18853233A HU E18853233 A HUE18853233 A HU E18853233A HU E061898 T2 HUE061898 T2 HU E061898T2
Authority
HU
Hungary
Prior art keywords
imidazo
pyrazine derivatives
pi3kdelta
inhibitors
pi3kdelta inhibitors
Prior art date
Application number
HUE18853233A
Other languages
English (en)
Inventor
Jing Li
Haibo Zhao
Zhiwei Wang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of HUE061898T2 publication Critical patent/HUE061898T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE18853233A 2017-09-08 2018-09-07 Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok HUE061898T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017101058 2017-09-08
CN2017119373 2017-12-28
CN2018086555 2018-05-11

Publications (1)

Publication Number Publication Date
HUE061898T2 true HUE061898T2 (hu) 2023-08-28

Family

ID=65633578

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18853233A HUE061898T2 (hu) 2017-09-08 2018-09-07 Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok

Country Status (21)

Country Link
US (3) US11220506B2 (hu)
EP (2) EP3679042B1 (hu)
JP (1) JP7128264B2 (hu)
KR (1) KR20200052297A (hu)
CN (2) CN111704615B (hu)
AU (2) AU2018328569B2 (hu)
BR (1) BR112020004500A2 (hu)
CA (1) CA3072842A1 (hu)
DK (1) DK3679042T3 (hu)
ES (1) ES2944658T3 (hu)
FI (1) FI3679042T3 (hu)
HU (1) HUE061898T2 (hu)
IL (1) IL272988B (hu)
MX (1) MX2020002630A (hu)
NZ (1) NZ761680A (hu)
PL (1) PL3679042T3 (hu)
PT (1) PT3679042T (hu)
SG (1) SG11202001286SA (hu)
TW (2) TWI817956B (hu)
WO (1) WO2019047915A1 (hu)
ZA (1) ZA202000875B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190091339A (ko) 2016-12-07 2019-08-05 베이진 엘티디 Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체
EP3679042B1 (en) 2017-09-08 2023-03-01 BeiGene, Ltd. IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
EP4061851A4 (en) * 2019-11-21 2023-12-20 BeiGene, Ltd. METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3 KINASE DELTA INHIBITORS
WO2022247886A1 (en) * 2021-05-27 2022-12-01 Beigene, Ltd. SALTS OF A PI3Kdelta INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE
MX2024003134A (es) * 2021-09-14 2024-04-10 Beigene Ltd Metodos de tratamiento del cancer utilizando una combinacion de inhibidores de btk e inhibidores de pi3 quinasa.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
JP4916883B2 (ja) 2003-10-15 2012-04-18 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
TW200738725A (en) * 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
WO2010120237A1 (en) 2009-04-15 2010-10-21 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
CA2756759C (en) * 2009-04-16 2017-11-07 Joaquin Pastor Fernandez Imidazopyrazines for use as kinase inhibitors
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
TW202214254A (zh) * 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
AR102220A1 (es) * 2015-10-08 2017-02-15 Incyte Corp Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
ES2871140T3 (es) * 2016-06-16 2021-10-28 Janssen Pharmaceutica Nv Derivados bicíclicos de piridina, pirazina y pirimidina como inhibidores de PI3K beta
KR20190091339A (ko) * 2016-12-07 2019-08-05 베이진 엘티디 Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체
EP3679042B1 (en) 2017-09-08 2023-03-01 BeiGene, Ltd. IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Also Published As

Publication number Publication date
ZA202000875B (en) 2021-07-28
TW201920116A (zh) 2019-06-01
TWI817956B (zh) 2023-10-11
US20220081447A1 (en) 2022-03-17
BR112020004500A2 (pt) 2020-12-01
MX2020002630A (es) 2020-07-20
US20200207774A1 (en) 2020-07-02
IL272988A (en) 2020-04-30
TW202336010A (zh) 2023-09-16
SG11202001286SA (en) 2020-03-30
ES2944658T3 (es) 2023-06-23
JP7128264B2 (ja) 2022-08-30
CN111704615A (zh) 2020-09-25
AU2023254925A1 (en) 2023-11-16
EP3679042B1 (en) 2023-03-01
JP2020534259A (ja) 2020-11-26
DK3679042T3 (da) 2023-05-01
KR20200052297A (ko) 2020-05-14
NZ761680A (en) 2023-03-31
FI3679042T3 (fi) 2023-05-15
US11905294B2 (en) 2024-02-20
PL3679042T3 (pl) 2023-09-04
US11220506B2 (en) 2022-01-11
CN111051312A (zh) 2020-04-21
CA3072842A1 (en) 2019-03-14
CN111704615B (zh) 2023-02-17
WO2019047915A1 (en) 2019-03-14
EP4219502A1 (en) 2023-08-02
IL272988B (en) 2022-08-01
US20240150361A1 (en) 2024-05-09
EP3679042A4 (en) 2021-01-13
EP3679042A1 (en) 2020-07-15
AU2018328569B2 (en) 2023-07-27
AU2018328569A1 (en) 2020-02-27
PT3679042T (pt) 2023-05-18

Similar Documents

Publication Publication Date Title
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物
IL265918B (en) Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
HK1258905A1 (zh) 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1256751A1 (zh) [1,2,4]三唑並[1,5-a]嘧啶-7-基化合物
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
IL247948B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound